drugset / Trial / NCT02315352
Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years
Phase 1
Completed
48 enrolled
Merck KGaA, Darmstadt, Germany
Swiss Tropical & Public Health Institute · collab
RandomizedCrossoverOpen-label
Summary
The primary objective of the trial is to compare the "overall palatability" of the new orally disintegrating L-Praziquantel (L-PZQ ODT), the new racemate PZQ ODT (Rac-PZQ ODT) and the current available racemate PZQ tablets (reference) as assessed by means of human gustatory sensation tests (100 millimeter \[mm\] visual analogue scale \[VAS\] scoring modified by the incorporation of a 5 point facial hedonic scale). The secondary objectives are * To obtain feedback from children regarding the taste of different formulations using an open ended questionnaire * To document any discomfort or other observation in relation to acceptance of the study medication
Timeline
- Start
- 2015-04
- Primary completion
- 2015-05
- Completion
- 2015-05
Publications
- Background CHMP. (2005). Reflection paper: formulation of choice for the paediatric population. EMA
- Mahende MK, Huber E, Kourany-Lefoll E, Ali A, Hayward B, Bezuidenhout D, Bagchus W, Kabanywanyi AM. Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study. PLoS Negl Trop Dis. 2021 Jun 9;15(6):e0007370. doi: 10.1371/journal.pntd.0007370. eCollection 2021 Jun.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levo-Praziquantel | Unknown | 150 mg | Oral |
| Subject | Praziquantel | Small molecule | 150 mg | Oral |
| Subject | Rac-PZQ | Unknown | 150 mg | Oral |
Indications
No indication recorded.